;PMID: 7756104
;source_file_994.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..42] = [t:0..42]
;1)sentence:[e:48..127] = [t:48..127]
;2)section:[e:131..176] = [t:131..176]
;3)section:[e:180..266] = [t:180..266]
;4)sentence:[e:270..377] = [t:270..377]
;5)sentence:[e:378..582] = [t:378..582]
;6)sentence:[e:583..801] = [t:583..801]
;7)sentence:[e:802..961] = [t:802..961]
;8)sentence:[e:963..1108] = [t:963..1108]
;9)sentence:[e:1109..1252] = [t:1109..1252]
;10)sentence:[e:1253..1417] = [t:1253..1417]
;11)section:[e:1421..1465] = [t:1421..1465]

;section 0 Span:0..42
;Br J Clin Pharmacol. 1995 Jan;39(1):77-80.
(SEC
  (FRAG (NNP:[0..2] Br) (NNP:[3..4] J) (NNP:[5..9] Clin)
        (NNP:[10..19] Pharmacol) (.:[19..20] .) (CD:[21..25] 1995)
        (::[26..33] Jan;39-LRB-) (CD:[33..34] 1) (-RRB-:[34..35] -RRB-)
        (CD:[35..38] :77) (::[38..39] -) (CD:[39..41] 80) (.:[41..42] .)))

;sentence 1 Span:48..127
;Evidence for a role of cytochrome P450 2D6 and 3A4 in ethylmorphine
;metabolism.
;[71..90]:cyp450:"cytochrome P450 2D6"
;[71..86]...[95..98]:cyp450:"cytochrome P450"..."3A4"
;[102..115]:substance:"ethylmorphine"
(SENT
  (NP-HLN
    (NP (NN:[48..56] Evidence))
    (PP (IN:[57..60] for)
      (NP
        (NP (DT:[61..62] a) (NN:[63..67] role))
        (PP (IN:[68..70] of)
          (NP
            (NML
              (NML-1 (NN:[71..81] cytochrome) (NN:[82..86] P450))
              (NN:[87..90] 2D6))
            (CC:[91..94] and)
            (NP
              (NML-1 (-NONE-:[94..94] *P*))
              (NN:[95..98] 3A4))))
        (PP (IN:[99..101] in)
          (NP (NN:[102..115] ethylmorphine) (NN:[116..126] metabolism)))))
    (.:[126..127] .)))

;section 2 Span:131..176
;Liu Z, Mortimer O, Smith CA, Wolf CR, Rane A.
(SEC
  (FRAG (NNP:[131..134] Liu) (NNP:[135..136] Z) (,:[136..137] ,)
        (NNP:[138..146] Mortimer) (NNP:[147..148] O) (,:[148..149] ,)
        (NNP:[150..155] Smith) (NNP:[156..158] CA) (,:[158..159] ,)
        (NNP:[160..164] Wolf) (NNP:[165..167] CR) (,:[167..168] ,)
        (NNP:[169..173] Rane) (NN:[174..176] A.)))

;section 3 Span:180..266
;Department of Clinical Pharmacology, Akademiska Hospital, Uppsala University,
; Sweden.
(SEC
  (FRAG (NNP:[180..190] Department) (IN:[191..193] of) (NNP:[194..202] Clinical)
        (NNP:[203..215] Pharmacology) (,:[215..216] ,)
        (NNP:[217..227] Akademiska) (NNP:[228..236] Hospital) (,:[236..237] ,)
        (NNP:[238..245] Uppsala) (NNP:[246..256] University) (IN:[256..257] ,)
        (NNP:[259..265] Sweden) (.:[265..266] .)))

;sentence 4 Span:270..377
;Ethylmorphine is metabolised by N-demethylation (to norethylmorphine) and by 
;O-deethylation (to morphine).
;[270..283]:substance:"Ethylmorphine"
;[322..338]:substance:"norethylmorphine"
;[367..375]:substance:"morphine"
(SENT
  (S
    (NP-SBJ-1 (NN:[270..283] Ethylmorphine))
    (VP (VBZ:[284..286] is)
      (VP (VBN:[287..298] metabolised)
        (NP-1 (-NONE-:[298..298] *))
        (PP-MNR
          (PP (IN:[299..301] by)
            (NP (NN:[302..317] N-demethylation)
              (PRN (-LRB-:[318..319] -LRB-)
                (PP (TO:[319..321] to)
                  (NP (NN:[322..338] norethylmorphine)))
                (-RRB-:[338..339] -RRB-))))
          (CC:[340..343] and)
          (PP (IN:[344..346] by)
            (NP (NN:[348..362] O-deethylation)
              (PRN (-LRB-:[363..364] -LRB-)
                (PP (TO:[364..366] to)
                  (NP (NN:[367..375] morphine)))
                (-RRB-:[375..376] -RRB-)))))))
    (.:[376..377] .)))

;sentence 5 Span:378..582
;The O-deethylation reaction was previously shown  in vivo to co-segregate
;with the O-demethylation of dextromethorphan indicating  that ethylmorphine
;is a substrate of polymorphic cytochrome P450(CYP)2D6.
;[480..496]:substance:"dextromethorphan"
;[514..527]:substance:"ethylmorphine"
;[533..542]:substance:"substrate"
;[558..581]:cyp450:"cytochrome P450(CYP)2D6"
(SENT
  (S
    (NP-SBJ-1 (DT:[378..381] The) (NN:[382..396] O-deethylation)
              (NN:[397..405] reaction))
    (VP (VBD:[406..409] was)
      (ADVP-TMP (RB:[410..420] previously))
      (VP (VBN:[421..426] shown)
        (NP-1 (-NONE-:[426..426] *))
        (ADVP (FW:[428..430] in) (FW:[431..435] vivo))
        (S
          (NP-SBJ-1 (-NONE-:[435..435] *))
          (VP (TO:[436..438] to)
            (VP (AFX:[439..441] co) (HYPH:[441..442] -)
                (VB:[442..451] segregate)
              (PP (IN:[452..456] with)
                (NP
                  (NP (DT:[457..460] the) (NN:[461..476] O-demethylation))
                  (PP (IN:[477..479] of)
                    (NP (NN:[480..496] dextromethorphan))))))))
        (S-ADV
          (NP-SBJ (-NONE-:[496..496] *))
          (VP (VBG:[497..507] indicating)
            (SBAR (IN:[509..513] that)
              (S
                (NP-SBJ (NN:[514..527] ethylmorphine))
                (VP (VBZ:[528..530] is)
                  (NP-PRD
                    (NP (DT:[531..532] a) (NN:[533..542] substrate))
                    (PP (IN:[543..545] of)
                      (NP (JJ:[546..557] polymorphic)
                        
                        (NML
                          (NML (NN:[558..568] cytochrome) (NN:[569..573] P450))
                          (NML (-LRB-:[573..574] -LRB-) (NN:[574..577] CYP)
                               (-RRB-:[577..578] -RRB-)))
                        (NN:[578..581] 2D6)))))))))))
    (.:[581..582] .)))

;sentence 6 Span:583..801
;To  study further the features of ethylmorphine metabolism we investigated
;its  N-demethylation and O-deethylation in human liver microsomes from eight 
;extensive (EM) and one poor metaboliser (PM) of dextromethorphan.
;[617..630]:substance:"ethylmorphine"
;[784..800]:substance:"dextromethorphan"
(SENT
  (S
    (S-PRP
      (NP-SBJ (-NONE-:[583..583] *))
      (VP (TO:[583..585] To)
        (VP (VB:[587..592] study)
          (ADVP (RB:[593..600] further))
          (NP
            (NP (DT:[601..604] the) (NNS:[605..613] features))
            (PP (IN:[614..616] of)
              (NP (NN:[617..630] ethylmorphine) (NN:[631..641] metabolism)))))))
    (NP-SBJ (PRP:[642..644] we))
    (VP (VBD:[645..657] investigated)
      (NP (PRP$:[658..661] its) (NN:[663..678] N-demethylation)
          (CC:[679..682] and) (NN:[683..697] O-deethylation))
      (PP-LOC (IN:[698..700] in)
        (NP
          (NP (JJ:[701..706] human) (NN:[707..712] liver)
              (NNS:[713..723] microsomes))
          (PP (IN:[724..728] from)
            (NP
              (NP
                (NP (CD:[729..734] eight)
                  (NML
                    (NML (JJ:[736..745] extensive)
                      (NML-1 (-NONE-:[745..745] *P*)))
                    (NML (-LRB-:[746..747] -LRB-) (NN:[747..749] EM)
                         (-RRB-:[749..750] -RRB-))))
                (CC:[751..754] and)
                (NP (CD:[755..758] one)
                  (NML
                    (NML (JJ:[759..763] poor)
                      (NML-1 (NN:[764..775] metaboliser)))
                    (NML (-LRB-:[776..777] -LRB-) (NN:[777..779] PM)
                         (-RRB-:[779..780] -RRB-)))))
              (PP (IN:[781..783] of)
                (NP (NN:[784..800] dextromethorphan))))))))
    (.:[800..801] .)))

;sentence 7 Span:802..961
;Whereas  N-demethylation varied only two-fold there was a 4.3-fold variation
;in the  O-deethylation of ethylmorphine, the lowest rate being observed in
;the PM.
;[839..847]:quantitative-value:"two-fold"
;[860..868]:quantitative-value:"4.3-fold"
;[905..918]:substance:"ethylmorphine"
(SENT
  (S
    (SBAR-ADV (IN:[802..809] Whereas)
      (S
        (NP-SBJ (NN:[811..826] N-demethylation))
        (VP (VBD:[827..833] varied)
          (ADVP-EXT
            (QP (RB:[834..838] only)
               (CD:[839..842] two) (HYPH:[842..843] -) (RB:[843..847] fold))))))
    (NP-SBJ (EX:[848..853] there))
    (VP (VBD:[854..857] was)
      (NP-PRD
        (NP (DT:[858..859] a)
          (QP (CD:[860..863] 4.3) (HYPH:[863..864] -) (JJ:[864..868] fold))
          (NN:[869..878] variation))
        (PP (IN:[879..881] in)
          (NP
            (NP (DT:[882..885] the) (NN:[887..901] O-deethylation))
            (PP (IN:[902..904] of)
              (NP (NN:[905..918] ethylmorphine))))))
      (,:[918..919] ,)
      (S-ADV
        (NP-SBJ-1 (DT:[920..923] the) (JJS:[924..930] lowest)
                  (NN:[931..935] rate))
        (VP (VBG:[936..941] being)
          (VP (VBN:[942..950] observed)
            (NP-1 (-NONE-:[950..950] *))
            (PP-LOC (IN:[951..953] in)
              (NP (DT:[954..957] the) (NN:[958..960] PM)))))))
    (.:[960..961] .)))

;sentence 8 Span:963..1108
;Quinidine, at a concentration of 1 microM, inhibited O-deethylation in 
;microsomes from an EM, but was unable to do so in microsomes from the PM.
;[963..972]:substance:"Quinidine"
;[996..997]:quantitative-value:"1"
;[998..1004]:quantitative-units:"microM"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[963..972] Quinidine))
      (,:[972..973] ,)
      (PP (IN:[974..976] at)
        (NP
          (NP (DT:[977..978] a) (NN:[979..992] concentration))
          (PP (IN:[993..995] of)
            (NP (CD:[996..997] 1) (NN:[998..1004] microM))))))
    (,:[1004..1005] ,)
    (VP
      (VP (VBD:[1006..1015] inhibited)
        (NP (NN:[1016..1030] O-deethylation))
        (PP-LOC (IN:[1031..1033] in)
          (NP
            (NP (NNS:[1035..1045] microsomes))
            (PP (IN:[1046..1050] from)
              (NP (DT:[1051..1053] an) (NN:[1054..1056] EM))))))
      (,:[1056..1057] ,) (CC:[1058..1061] but)
      (VP (VBD:[1062..1065] was)
        (ADJP-PRD (JJ:[1066..1072] unable)
          (S
            (NP-SBJ (-NONE-:[1072..1072] *))
            (VP (TO:[1073..1075] to)
              (VP (VB:[1076..1078] do)
                (ADVP (RB:[1079..1081] so))
                (PP-LOC (IN:[1082..1084] in)
                  (NP
                    (NP (NNS:[1085..1095] microsomes))
                    (PP (IN:[1096..1100] from)
                      (NP (DT:[1101..1104] the) (NN:[1105..1107] PM)))))))))))
    (.:[1107..1108] .)))

;sentence 9 Span:1109..1252
;The  immunoidentified CYP2D6 and CYP3A4 correlated with the rates of
;O-deethylation  (r = 0.972) and N-demethylation (r = 0.969), respectively.
;[1131..1137]:cyp450:"CYP2D6"
;[1142..1148]:cyp450:"CYP3A4"
(SENT
  (S
    (NP-SBJ (DT:[1109..1112] The)
      (NML
        (NML
          (ADJP-1 (VBN:[1114..1130] immunoidentified))
          (NN:[1131..1137] CYP2D6))
        (CC:[1138..1141] and)
        (NML
          (ADJP-1 (-NONE-:[1141..1141] *P*))
          (NN:[1142..1148] CYP3A4))))
    (VP (VBD:[1149..1159] correlated)
      (PP-CLR (IN:[1160..1164] with)
        (NP
          (NP (DT:[1165..1168] the) (NNS:[1169..1174] rates))
          (PP (IN:[1175..1177] of)
            (NP
              (NP (NN:[1178..1192] O-deethylation)
                (PRN (-LRB-:[1194..1195] -LRB-)
                  (S
                    (NP-SBJ (NN:[1195..1196] r))
                    (VP (SYM:[1197..1198] =)
                      (NP (CD:[1199..1204] 0.972))))
                  (-RRB-:[1204..1205] -RRB-)))
              (CC:[1206..1209] and)
              (NP (NN:[1210..1225] N-demethylation)
                (PRN (-LRB-:[1226..1227] -LRB-)
                  (S
                    (NP-SBJ (NN:[1227..1228] r))
                    (VP (SYM:[1229..1230] =)
                      (NP (CD:[1231..1236] 0.969))))
                  (-RRB-:[1236..1237] -RRB-)))))))
      (,:[1237..1238] ,)
      (ADVP (RB:[1239..1251] respectively)))
    (.:[1251..1252] .)))

;sentence 10 Span:1253..1417
;We conclude that the  O-deethylation of ethylmorphine is catalysed by the
;CYP2D6 in human liver  microsomes consistent with previous findings in
;healthy volunteers.
;[1293..1306]:substance:"ethylmorphine"
;[1327..1333]:cyp450:"CYP2D6"
(SENT
  (S
    (NP-SBJ (PRP:[1253..1255] We))
    (VP (VBP:[1256..1264] conclude)
      (SBAR (IN:[1265..1269] that)
        (S
          (NP-SBJ-1
            (NP (DT:[1270..1273] the) (NN:[1275..1289] O-deethylation))
            (PP (IN:[1290..1292] of)
              (NP (NN:[1293..1306] ethylmorphine))))
          (VP (VBZ:[1307..1309] is)
            (VP (VBN:[1310..1319] catalysed)
              (NP-1 (-NONE-:[1319..1319] *))
              (PP (IN:[1320..1322] by)
                (NP-LGS
                  (NP (DT:[1323..1326] the) (NN:[1327..1333] CYP2D6))
                  (PP-LOC (IN:[1334..1336] in)
                    (NP (JJ:[1337..1342] human) (NN:[1343..1348] liver)
                        (NNS:[1350..1360] microsomes)))))
              (S-ADV
                (NP-SBJ (-NONE-:[1360..1360] *))
                (ADJP-PRD (JJ:[1361..1371] consistent)
                  (PP (IN:[1372..1376] with)
                    (NP
                      (NP (JJ:[1377..1385] previous) (NNS:[1386..1394] findings))
                      (PP-LOC (IN:[1395..1397] in)
                        (NP (JJ:[1398..1405] healthy)
                            (NNS:[1406..1416] volunteers))))))))))))
    (.:[1416..1417] .)))

;section 11 Span:1421..1465
;PMID: 7756104 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1421..1425] PMID) (::[1425..1426] :) (CD:[1427..1434] 7756104)
        (NN:[1435..1436] -LSB-) (NNP:[1436..1442] PubMed) (::[1443..1444] -)
        (NN:[1445..1452] indexed) (IN:[1453..1456] for)
        (NNP:[1457..1465] MEDLINE-RSB-)))
